MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monks, A.
Right arrow Articles by Sausville, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monks, A.
Right arrow Articles by Sausville, E. A.

Vol. 63, Issue 3, 766-772, March 2003

Genotoxic Profiling of MCF-7 Breast Cancer Cell Line Elucidates Gene Expression Modifications Underlying Toxicity of the Anticancer Drug 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole

Anne Monks, Erik Harris, Curtis Hose, John Connelly, and Edward A. Sausville

SAIC-Frederick Inc., Screening Technologies Branch, Laboratory of Functional Genomics, National Cancer Institute-Frederick, Frederick, Maryland (A.M., E.H., C.H., J.C.); and Developmental Therapeutics Program, National Cancer Institute, Rockville, Maryland (E.A.S.)

A candidate antitumor agent, 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F-203), was empirically discovered through the National Cancer Institute's Anticancer Drug Screen from a unique growth inhibitory-response profile, indicating a novel mechanism of action. 5F-203 activates the CYP1 family of cytochrome P450, involving aryl hydrocarbon receptor translocation into the nucleus. To characterize more completely the pathways involved in 5F-203 toxicity, cDNA microarrays were used to determine gene expression changes in MCF-7, a 5F-203-sensitive breast cancer cell line, after treatment with 1 µM 5F-203. The mRNA expression of CYP1A1 and CYP1B1 were both increased approximately 20-fold after 24 h, but less after 6 h of treatment, confirming previous results. However, the most pronounced drug-induced change was in the PLAB gene, encoding one of the bone morphogenic proteins in the transforming growth factor-beta (TGF-beta ) superfamily. Other induced gene expressions included the apoptosis-initiating receptor TNFRSF6 (CD95/FAS), the DNA-damage response genes CDKN1A (p21/Cip1), p53-induced gene-3, and DNA binding protein 2. In contrast, the transcription factor c-Myc showed reduced expression. Western blot analysis also showed induction of p53 protein expression in response to 5F-203 treatment. In contrast to the MCF-7 data, MDA-MB-435, a cancer cell line resistant to 5F-203, showed no change in expression of any of these genes or the p53 protein under the same conditions of 5F-203 treatment. These data are consistent with the idea that CYP1A1 and CYP1B1 activation leads to 5F-203 toxicity through DNA damage-induced apoptosis, as well as signaling through a variant member of the TGF-beta superfamily.

Copyright © 2003 by U.S. Government


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
V. Soto-Cerrato, F. Vinals, J. R. Lambert, J. A. Kelly, and R. Perez-Tomas
Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3{beta} activity in human breast cancer cells
Mol. Cancer Ther., January 1, 2007; 6(1): 362 - 369.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. M. Martinez, T. Sali, R. Okazaki, C. Anna, M. Hollingshead, C. Hose, A. Monks, N. J. Walker, S. J. Baek, and T. E. Eling
Drug-Induced Expression of Nonsteroidal Anti-Inflammatory Drug-Activated Gene/Macrophage Inhibitory Cytokine-1/Prostate-Derived Factor, a Putative Tumor Suppressor, Inhibits Tumor Growth
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 899 - 906.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S.-H. Lee, K. Yamaguchi, J.-S. Kim, T. E. Eling, S. Safe, Y. Park, and S. J. Baek
Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner
Carcinogenesis, May 1, 2006; 27(5): 972 - 981.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Yamaguchi, S.-H. Lee, T. E. Eling, and S. J. Baek
A novel peroxisome proliferator-activated receptor {gamma} ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells
Mol. Cancer Ther., May 1, 2006; 5(5): 1352 - 1361.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Boyer, W. L. Allen, E. G. McLean, P. M. Wilson, A. McCulla, S. Moore, D. B. Longley, C. Caldas, and P. G. Johnston
Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.
Cancer Res., March 1, 2006; 66(5): 2765 - 2777.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J.-S. Kim, S. J. Baek, T. Sali, and T. E. Eling
The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15
Mol. Cancer Ther., March 1, 2005; 4(3): 487 - 493.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. J. Baek, J.-S. Kim, S. M. Moore, S.-H. Lee, J. Martinez, and T. E. Eling
Cyclooxygenase Inhibitors Induce the Expression of the Tumor Suppressor Gene EGR-1, Which Results in the Up-Regulation of NAG-1, an Antitumorigenic Protein
Mol. Pharmacol., February 1, 2005; 67(2): 356 - 364.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. Brantley, V. Trapani, M. C. Alley, C. D. Hose, T. D. Bradshaw, M. F. G. Stevens, E. A. Sausville, and S. F. Stinson
FLUORINATED 2-(4-AMINO-3-METHYLPHENYL)BENZOTHIAZOLES INDUCE CYP1A1 EXPRESSION, BECOME METABOLIZED, AND BIND TO MACROMOLECULES IN SENSITIVE HUMAN CANCER CELLS
Drug Metab. Dispos., December 1, 2004; 32(12): 1392 - 1401.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. J. Baek, J.-S. Kim, F. R. Jackson, T. E. Eling, M. F. McEntee, and S.-H. Lee
Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells
Carcinogenesis, December 1, 2004; 25(12): 2425 - 2432.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Yamaguchi, S.-H. Lee, T. E. Eling, and S. J. Baek
Identification of Nonsteroidal Anti-inflammatory Drug-activated Gene (NAG-1) as a Novel Downstream Target of Phosphatidylinositol 3-Kinase/AKT/GSK-3{beta} Pathway
J. Biol. Chem., November 26, 2004; 279(48): 49617 - 49623.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics